MX2015011371A - Anti-(+) --methamphetamine monoclonal antibodies. - Google Patents
Anti-(+) --methamphetamine monoclonal antibodies.Info
- Publication number
- MX2015011371A MX2015011371A MX2015011371A MX2015011371A MX2015011371A MX 2015011371 A MX2015011371 A MX 2015011371A MX 2015011371 A MX2015011371 A MX 2015011371A MX 2015011371 A MX2015011371 A MX 2015011371A MX 2015011371 A MX2015011371 A MX 2015011371A
- Authority
- MX
- Mexico
- Prior art keywords
- methamphetamine
- monoclonal antibodies
- subject
- methamphetamine monoclonal
- slowing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of methamphetamine use, or for slowing the rate of (+) methamphetamine entry into the brain of a subject. The method comprises administering an effective amount of an anti-(+) methamphetamine antibody to a subject.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/802,688 US9023353B2 (en) | 2013-03-13 | 2013-03-13 | Anti-(+)—methamphetamine monoclonal antibodies |
PCT/US2014/025890 WO2014160133A2 (en) | 2013-03-13 | 2014-03-13 | Anti-(+) --methamphetamine monoclonal antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015011371A true MX2015011371A (en) | 2015-12-16 |
Family
ID=51527982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015011371A MX2015011371A (en) | 2013-03-13 | 2014-03-13 | Anti-(+) --methamphetamine monoclonal antibodies. |
Country Status (11)
Country | Link |
---|---|
US (1) | US9023353B2 (en) |
EP (1) | EP2970503B1 (en) |
JP (2) | JP2016514153A (en) |
AU (1) | AU2014244120B2 (en) |
BR (1) | BR112015020718A2 (en) |
CA (1) | CA2901514C (en) |
ES (1) | ES2923643T3 (en) |
HK (1) | HK1215714A1 (en) |
MX (1) | MX2015011371A (en) |
PL (1) | PL2970503T3 (en) |
WO (1) | WO2014160133A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7632929B2 (en) | 2000-04-20 | 2009-12-15 | The Board Of Trustees Of The University Of Arkansas | Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof |
CN117088982A (en) * | 2022-05-11 | 2023-11-21 | 东莞市朋志生物科技有限公司 | Anti-methamphetamine antibodies, reagents and kits for detecting methamphetamine |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5041076A (en) | 1967-01-10 | 1991-08-20 | Kantor Frederick W | Rotary inertial thermodynamic multi-stage mass-flow divider |
US4041076A (en) | 1974-10-23 | 1977-08-09 | Hoffmann-La Roche Inc. | Immunoassay for pharmacologically active phenethylamines |
US4329281A (en) | 1978-06-05 | 1982-05-11 | Hoffmann-La Roche Inc. | Hapten compositions |
AU528246B2 (en) | 1978-10-14 | 1983-04-21 | Teikoku Hormone Mfg. Co., Ltd. | Stable immunoassay reagent for hapten determination |
DK159276C (en) | 1980-03-31 | 1991-02-18 | Takeda Chemical Industries Ltd | PROCEDURE FOR THE ISOLATION OF SPECIFIC ANTIBODIES AND ENZYM IMMUNE DETERMINATION METHOD USING THE ISOLATED ANTIBODY |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5160701A (en) | 1986-02-18 | 1992-11-03 | Abbott Laboratories | Solid-phase analytical device and method for using same |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
JPH0737986B2 (en) | 1988-03-29 | 1995-04-26 | 松下電器産業株式会社 | Immunological detection method |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5135863A (en) | 1988-12-23 | 1992-08-04 | Syntex (U.S.A.) Inc. | Compositions and methods for determining the presence of amphetamines in a sample suspected of containing amphetamine and/or methamphetamine |
US5252496A (en) | 1989-12-18 | 1993-10-12 | Princeton Biomeditech Corporation | Carbon black immunochemical label |
US5141850A (en) | 1990-02-07 | 1992-08-25 | Hygeia Sciences, Inc. | Porous strip form assay device method |
US5238652A (en) | 1990-06-20 | 1993-08-24 | Drug Screening Systems, Inc. | Analytical test devices for competition assay for drugs of non-protein antigens using immunochromatographic techniques |
CH678394A5 (en) | 1990-08-22 | 1991-09-13 | Cerny Erich H | |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2108048T3 (en) | 1990-08-29 | 1997-12-16 | Genpharm Int | PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5451504A (en) | 1991-07-29 | 1995-09-19 | Serex, Inc. | Method and device for detecting the presence of analyte in a sample |
CA2096495C (en) | 1992-06-16 | 2002-07-09 | Kathy Palmer Ordonez | Dual analyte immunoassay |
US5415994A (en) | 1993-08-02 | 1995-05-16 | Quidel Corporation | Lateral flow medical diagnostic assay device with sample extraction means |
US5492841A (en) | 1994-02-18 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Quaternary ammonium immunogenic conjugates and immunoassay reagents |
US5620890A (en) | 1995-03-14 | 1997-04-15 | The United States Of America As Represented By The Secretary Of Agriculture | Monoclonal antibodies to hygromycin B and the method of making the same |
US5690942A (en) | 1995-06-02 | 1997-11-25 | American Home Products Corporation | Adjuvants for viral vaccines |
EP1378525A3 (en) | 1996-06-07 | 2004-01-14 | Neorx Corporation | Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods |
IT1284076B1 (en) | 1996-06-27 | 1998-05-08 | Dox Al Italia Spa | F(AB')2 FRAGMENTS AND THEIR IMMUNOGLOBULINS IGG, ACTIVE AS SPECIFIC ANTIBODY TOWARDS DRUGS AND THEIR METABOLITES, AND THEIR |
DE19630102A1 (en) | 1996-07-25 | 1998-01-29 | Boehringer Mannheim Gmbh | New activated amphetamines |
US6087184A (en) | 1997-11-10 | 2000-07-11 | Beckman Coulter, Inc. | Opposable-element chromatographic assay device for detection of analytes |
US6306616B1 (en) | 1998-03-27 | 2001-10-23 | Microgenics Corporation | Adsorption type confirmatory assays |
WO2001055325A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
US7202348B2 (en) | 2000-04-20 | 2007-04-10 | The University Of Arkansas For Medical Sciences | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs |
AU2001255537A1 (en) | 2000-04-20 | 2001-11-07 | The Board Of Trustees Of The University Of Arkansas | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs |
US7632929B2 (en) | 2000-04-20 | 2009-12-15 | The Board Of Trustees Of The University Of Arkansas | Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof |
US6669937B2 (en) | 2000-04-20 | 2003-12-30 | The Board Of Trustees Of The University Of Arkansas | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs |
US20030171435A1 (en) | 2002-01-23 | 2003-09-11 | Drug Abuse Sciences, Inc. | New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them |
EP1331219A1 (en) | 2002-01-23 | 2003-07-30 | Drug Abuse Sciences, Inc. | New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them |
EP1333023B1 (en) | 2002-01-31 | 2010-12-22 | Randox Laboratories Ltd. | Immunogens, antibodies and conjugates to ketamine and its metabolites |
WO2004050032A2 (en) | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies against drugs of abuse |
US20040242848A1 (en) | 2003-04-21 | 2004-12-02 | Owens S. Michael | Mouse/human chimeric anti-phencyclidine antibody and uses thereof |
US7674884B2 (en) * | 2003-12-10 | 2010-03-09 | Novimmune S.A. | Neutralizing antibodies and methods of use thereof |
US7037669B2 (en) | 2004-03-22 | 2006-05-02 | Dade Behring Inc. | Assays for amphetamine and methamphetamine using stereospecific reagents |
US7294649B2 (en) | 2004-12-17 | 2007-11-13 | Roche Diagnostics Operatins, Inc. | Methamphetamine derivatives and conjugates for immunoassay |
ES2415655T3 (en) * | 2006-06-15 | 2013-07-26 | The Board Of Trustees Of The University Of Arkansas | Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine-like compounds |
US8853146B2 (en) * | 2007-04-20 | 2014-10-07 | The Board Of Trustees Of The University Of Arkansas | Hapten compounds and compositions and uses thereof |
US20100092470A1 (en) | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
EP2542588A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
-
2013
- 2013-03-13 US US13/802,688 patent/US9023353B2/en active Active
-
2014
- 2014-03-13 PL PL14775035.0T patent/PL2970503T3/en unknown
- 2014-03-13 AU AU2014244120A patent/AU2014244120B2/en active Active
- 2014-03-13 EP EP14775035.0A patent/EP2970503B1/en active Active
- 2014-03-13 ES ES14775035T patent/ES2923643T3/en active Active
- 2014-03-13 CA CA2901514A patent/CA2901514C/en active Active
- 2014-03-13 MX MX2015011371A patent/MX2015011371A/en unknown
- 2014-03-13 BR BR112015020718A patent/BR112015020718A2/en not_active Application Discontinuation
- 2014-03-13 WO PCT/US2014/025890 patent/WO2014160133A2/en active Application Filing
- 2014-03-13 JP JP2016501990A patent/JP2016514153A/en active Pending
-
2016
- 2016-03-30 HK HK16103673.0A patent/HK1215714A1/en unknown
-
2018
- 2018-12-06 JP JP2018229046A patent/JP6560808B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2019069957A (en) | 2019-05-09 |
JP2016514153A (en) | 2016-05-19 |
US20140271686A1 (en) | 2014-09-18 |
EP2970503A4 (en) | 2016-11-30 |
JP6560808B2 (en) | 2019-08-14 |
EP2970503B1 (en) | 2022-06-22 |
WO2014160133A3 (en) | 2014-11-27 |
BR112015020718A2 (en) | 2017-10-10 |
WO2014160133A2 (en) | 2014-10-02 |
CA2901514C (en) | 2021-02-16 |
CA2901514A1 (en) | 2014-10-02 |
ES2923643T3 (en) | 2022-09-29 |
EP2970503A2 (en) | 2016-01-20 |
US9023353B2 (en) | 2015-05-05 |
AU2014244120B2 (en) | 2018-07-19 |
HK1215714A1 (en) | 2016-09-09 |
AU2014244120A1 (en) | 2015-09-03 |
PL2970503T3 (en) | 2022-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004503A (en) | Humanized or chimeric cd3 antibodies. | |
MX2022011002A (en) | Humanized or chimeric cd3 antibodies. | |
MX2022002364A (en) | Anti-pd-l1 antibodies. | |
MX2016002826A (en) | Anti-b7-h1 antibodies for treating tumors. | |
MX2021002406A (en) | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor. | |
PH12015502293A1 (en) | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use | |
MX2018008934A (en) | Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same. | |
MX2016008098A (en) | Bispecific her2 antibodies and methods of use. | |
TN2015000396A1 (en) | Antibody drug conjugates | |
WO2016062722A8 (en) | Combination | |
MX2015017331A (en) | Anti-fcrh5 antibodies. | |
EA201591750A1 (en) | ANTIBODIES AGAINST B7-H4 AND IMMUNOCONJUGATES | |
MX2021008755A (en) | Methods of treating a tauopathy. | |
PH12017500864A1 (en) | Anti-notch1 antibodies | |
PH12016501976A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
MX2019015604A (en) | Methods of treating a tauopathy. | |
MX359794B (en) | Anti-hepcidin antibodies and uses thereof. | |
MX2023006415A (en) | Antibodies, uses & methods. | |
BR112018003526A2 (en) | methods of treating inflammatory diseases | |
MX2017001686A (en) | Anti-ceramide antibodies. | |
EA201690446A1 (en) | TREATMENT OF MULTIPLE MYELOMA | |
MX2015011371A (en) | Anti-(+) --methamphetamine monoclonal antibodies. | |
CL2016000999A1 (en) | Specific anti-cd38 antibodies to treat human cancers | |
MX2019014291A (en) | Treatment method. |